CBER’s New Home For Gene Therapies: OTAT Changes To OTP But Leadership Questions Remain
Executive Summary
US FDA has not named permanent heads of several offices within the new Office of Therapeutic Products, the only super office in the Center for Biologics Evaluation and Research.
You may also be interested in...
Gene Therapy Sponsors Claim US FDA ‘Processing Error’ Could Cause Delays
Office of Therapeutic Products Director Nicole Verdun says the problem is uncommon and sometimes relates to missing manufacturing information.
US FDA’s Gene Therapy Office Poaches OCE’s Fashoyin-Aje For Oncology Position
Lola Fashoyin-Aje, formerly associate director of the Oncology Center of Excellence, will become director of the CBER Office of Therapeutic Products’ Office of Clinical Evaluation.
Gene Therapy: Nonclinical Questions Do Not Seem Ideal For The US FDA’s New Type D Meeting
Nonclinical testing questions should be answered in a pre-IND meeting, rather than the new Type D session. A US FDA Center for Biologics Evaluation and Research official also indicated support for alternatives to animal testing when possible.